Chembio Stock Analysis


USD 0.90  0.13  12.62%   

The current price rise of Chembio Diagnostics could raise concerns from stockholders as the firm is trading at a share price of 0.9 on 541,737 in volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in September. The stock standard deviation of daily returns for 90 days investing horizon is currently 8.38. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Chembio Diagnostics partners.
Continue to Trending Equities.
The Chembio Diagnostics stock analysis report makes it easy to digest most publicly released information about Chembio Diagnostics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Chembio Stock analysis module also helps to analyze the Chembio Diagnostics price relationship with some important fundamental indicators such as market cap and management efficiency.

Chembio Stock Analysis Notes

The company has price-to-book (P/B) ratio of 0.69. Some equities with similar Price to Book (P/B) outperform the market in the long run. Chembio Diagnostics recorded a loss per share of 1.24. The entity had not issued any dividends in recent years. The firm had 1:8 split on the 30th of May 2012. Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or diagnose diseases. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York. Chembio Diagnostics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 337 people. For more info on Chembio Diagnostics please contact John Sperzel at 631 924-2065 or go to

Chembio Diagnostics Quarterly Cost of Revenue

8.09 Million

Chembio Diagnostics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Chembio Diagnostics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Chembio Diagnostics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Chembio Diagnostics is way too risky over 90 days horizon
Chembio Diagnostics has some characteristics of a very speculative penny stock
Chembio Diagnostics appears to be risky and price may revert if volatility continues
Chembio Diagnostics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 57.91 M. Net Loss for the year was (38.19 M) with profit before overhead, payroll, taxes, and interest of 12.83 M.
Chembio Diagnostics currently holds about 24.4 M in cash with (27.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81.
Latest headline from Chembio Diagnostics to Report Second Quarter 2022 Financial Results on August 4, 2022 -

Chembio Diagnostics Upcoming and Recent Events

Earnings reports are used by Chembio Diagnostics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Chembio Diagnostics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report10th of March 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End10th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Chembio Largest EPS Surprises

Earnings surprises can significantly impact Chembio Diagnostics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Chembio Diagnostics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Chembio Diagnostics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Chembio Diagnostics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Chembio Diagnostics specific information freely available to individual and institutional investors to make a timely investment decision.
4th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
26th of May 2022
Submission of Matters to a Vote of Security Holders
5th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
7th of April 2022
Financial Statements and Exhibits. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3rd of March 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
14th of February 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Entry into a Material Definitive Agreement
9th of February 2022
Unclassified Corporate Event
6th of January 2022
Financial Statements and Exhibits. Other Events. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Entry into a Material Definitive Agreement

Chembio Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 33.05 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Chembio Diagnostics's market, we take the total number of its shares issued and multiply it by Chembio Diagnostics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Chembio Profitablity

Chembio Diagnostics' profitability indicators refer to fundamental financial ratios that showcase Chembio Diagnostics' ability to generate income relative to its revenue or operating costs. If, let's say, Chembio Diagnostics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Chembio Diagnostics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Chembio Diagnostics' profitability requires more research than a typical breakdown of Chembio Diagnostics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (65.95) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (43.58) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.44.
Last ReportedProjected for 2022
Return on Investment(62.44) (64.08) 
Return on Average Assets(0.51) (0.53) 
Return on Average Equity(1.12) (1.16) 
Return on Invested Capital(0.59) (0.61) 
Return on Sales(0.65) (0.67) 

Management Efficiency

The entity has return on total asset (ROA) of (26.23) % which means that it has lost $26.23 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (153.33) %, meaning that it created substantial loss on money invested by shareholders. Chembio Diagnostics management efficiency ratios could be used to measure how well chembio diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -64.08. The current Return on Average Assets is estimated to decrease to -0.53. Chembio Diagnostics Revenue to Assets are most likely to slightly decrease in the upcoming years. The last year's value of Revenue to Assets was reported at 0.65. The current Asset Turnover is estimated to increase to 0.84, while Total Assets are projected to decrease to roughly 58.3 M.
Last ReportedProjected for 2022
Book Value per Share 1.41  1.46 
Enterprise Value over EBIT(1.00) (1.08) 
Enterprise Value over EBITDA(0.86) (0.93) 
Price to Book Value 1.00  1.03 
Tangible Assets Book Value per Share 2.89  2.85 
Enterprise Value24.2 M24.8 M
Tangible Asset Value70.2 M75.8 M

Technical Drivers

As of the 9th of August, Chembio Diagnostics shows the risk adjusted performance of 0.1777, and Mean Deviation of 5.52. Chembio Diagnostics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have collected data for nineteen technical drivers for Chembio Diagnostics, which can be compared to its rivals. Please confirm Chembio Diagnostics coefficient of variation and the relationship between the jensen alpha and skewness to decide if Chembio Diagnostics is priced correctly, providing market reflects its regular price of 0.9 per share. Given that Chembio Diagnostics is a hitting penny stock territory we recommend to closely look at its total risk alpha.

Chembio Diagnostics Price Movement Analysis

The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The MESA Adaptive Moving Average indicator adapts to Chembio Diagnostics price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator.

Chembio Diagnostics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Chembio Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Chembio Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Chembio Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Chembio Diagnostics Predictive Daily Indicators

Chembio Diagnostics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Chembio Diagnostics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Chembio Diagnostics Forecast Models

Chembio Diagnostics time-series forecasting models is one of many Chembio Diagnostics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Chembio Diagnostics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Chembio Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Chembio Diagnostics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Chembio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Chembio Diagnostics. By using and applying Chembio Stock analysis, traders can create a robust methodology for identifying Chembio entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(64.94) (66.65) 
EBITDA Margin(0.59) (0.60) 
Gross Margin 0.28  0.31 
Profit Margin(0.71) (0.73) 
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or diagnose diseases. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York. Chembio Diagnostics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 337 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Chembio Diagnostics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Piotroski F Score Now


Piotroski F Score

Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
All  Next Launch Module
Continue to Trending Equities. Note that the Chembio Diagnostics information on this page should be used as a complementary analysis to other Chembio Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Chembio Stock analysis

When running Chembio Diagnostics price analysis, check to measure Chembio Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chembio Diagnostics is operating at the current time. Most of Chembio Diagnostics' value examination focuses on studying past and present price action to predict the probability of Chembio Diagnostics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chembio Diagnostics' price. Additionally, you may evaluate how the addition of Chembio Diagnostics to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Is Chembio Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chembio Diagnostics. If investors know Chembio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chembio Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
33.2 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Chembio Diagnostics is measured differently than its book value, which is the value of Chembio that is recorded on the company's balance sheet. Investors also form their own opinion of Chembio Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Chembio Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chembio Diagnostics' market value can be influenced by many factors that don't directly affect Chembio Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chembio Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine Chembio Diagnostics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chembio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.